Posted by Michael Wonder on 30 Aug 2023
Zai Lab announces breakthrough therapy designation granted for repotrectinib for treatment of patients with NTRK positive TKI-pretreated advanced solid tumours in China
30 August 2023 - Candidate precision medicine has shown encouraging clinical activity for both ROS1 positive NSCLC and NTRK fusion-positive advanced solid tumors.
Zai Lab today announced that the Center for Drug Evaluation of the NMPA granted breakthrough therapy designation for investigational repotrectinib for the treatment of patients with advanced solid tumours that have an NTRK gene fusion who have progressed following treatment with TRK tyrosine kinase inhibitors.
